MCRB
HEALTHCARESeres Therapeutics Inc
$8.00+0.50 (+6.67%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MCRB Today?
No stock-specific AI insight has been generated for MCRB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.53$29.98
$8.00
Fundamentals
Market Cap$77M
P/E Ratio—
EPS$-5.20
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume110K
Avg Volume (10D)—
Shares Outstanding9.7M
MCRB News
20 articles- Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 5, 2026
- Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel DiseaseYahoo Finance·May 4, 2026
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026GlobeNewswire Inc.·Apr 20, 2026
- Seres Therapeutics to Present at CARB-X Investor DayYahoo Finance·Apr 9, 2026
- Seres Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 12, 2026
- Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business UpdatesYahoo Finance·Mar 2, 2026
- Sector Update: Health Care Stocks Rise Late AfternoonYahoo Finance·Feb 12, 2026
- Seres to lay off staff, pause top program in latest rebootBiopharmadive·Feb 12, 2026
- Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune DiseasesYahoo Finance·Feb 12, 2026
- Particles for Humanity Appoints Marcus Chapman as Senior Vice President and Head of FinanceYahoo Finance·Jan 13, 2026
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic StrategyYahoo Finance·Jan 6, 2026
- 3 Beaten-Down Biotech Stocks to Buy for a 2026 TurnaroundYahoo Finance·Dec 29, 2025
- Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceYahoo Finance·Nov 24, 2025
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Nov 5, 2025
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025Yahoo Finance·Oct 30, 2025
- Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155Yahoo Finance·Oct 29, 2025
- Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell TransplantYahoo Finance·Oct 14, 2025
- Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash RunwayYahoo Finance·Sep 23, 2025
- All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to BuyYahoo Finance·Sep 9, 2025
All 20 articles loaded
Price Data
Open$7.44
Previous Close$7.50
Day High$7.74
Day Low$7.44
52 Week High$29.98
52 Week Low$6.53
52-Week Range
$6.53$29.98
$8.00
Fundamentals
Market Cap$77M
P/E Ratio—
EPS$-5.20
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume110K
Avg Volume (10D)—
Shares Outstanding9.7M
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—